Tissue catalyzed growth of polymer as epithelial linings for therapy

Abstract

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

1 - 112 . (canceled) 
     
     
         113 . A composition suitable for oral administration comprising dopamine and an oxygen source, wherein the oxygen source reacts with a catalyst in a small intestine of a subject to release oxygen from the oxygen source to polymerize the dopamine on the lumen of the small intestine. 
     
     
         114 - 115 . (canceled) 
     
     
         116 . The composition of  claim 113 , wherein the composition comprises about 0.001 to about 500 mg/mL of dopamine. 
     
     
         117 . The composition of  claim 113 , wherein the composition comprises about 0.01 to about 50 mg/mL of dopamine. 
     
     
         118 - 121 . (canceled) 
     
     
         122 . The composition of  claim 113 , wherein the composition comprises about 1 to about 30 mM of the oxygen source. 
     
     
         123 - 124 . (canceled) 
     
     
         125 . The composition of  claim 113 , where the composition has a pH of about 7 to about 9. 
     
     
         126 . The composition of  claim 113 , wherein the composition further comprises a buffer. 
     
     
         127 . The composition of  claim 126 , wherein the buffer comprises phosphate, acetate, citrate, N-[tris(hydroxymethyl)methyl]glycine), (tris(hydroxymethyl)aminomethane), or (2-(bis(2-hydroxyethyl)amino)acetic acid). 
     
     
         128 . The composition of  claim 127 , wherein the buffer comprises tris(hydroxymethyl)aminomethane. 
     
     
         129 . The composition of  claim 113 , wherein the composition further comprises a digestive enzyme, a nutrient blocker, a nutraceutical, a radioprotective agent, an active pharmaceutical ingredient, a diagnostic agent, or a combination thereof. 
     
     
         130 . The composition of  claim 113 , wherein the composition is a liquid or solid dosage form. 
     
     
         131 . The composition of  claim 113 , wherein the composition is in the form of a solution, a gel, a tablet, or a capsule. 
     
     
         132 - 148 . (canceled) 
     
     
         149 . A kit comprising:
 the composition of  claim 113 , and   instructions for administering the composition to a subject.   
     
     
         150 . The kit of  claim 149 , wherein the composition comprises:
 dopamine;   hydrogen peroxide or urea hydrogen peroxide;   a buffer; and   optionally, an enzyme, a nutrient blocker, a nutraceutical, a radioprotective agent, an active pharmaceutical ingredient, a diagnostic agent, or a combination thereof.   
     
     
         151 . The kit of  claim 150 , wherein the buffer is tris(hydroxymethyl)aminomethane. 
     
     
         152 . The kit of  claim 149 , wherein the composition is in the form of a capsule. 
     
     
         153 . The kit of  claim 149 , wherein the kit further comprises an endoscope, arthroscope, cystoscope, colposcope, colonoscope, bronchoscope, ureteroscope, anoscope, esophagoscope, gastroscope, laparoscope, laryngoscope, neuroendoscope, proctoscope, sigmoidoscope, or thoracoscope. 
     
     
         154 . (canceled) 
     
     
         155 . The composition of  claim 129 , wherein the composition further comprises a digestive enzyme. 
     
     
         156 . The composition of  claim 155 , wherein the digestive enzyme is selected from lactase, peptidase, sucrase, maltase, amylase, a lipase, or a protease. 
     
     
         157 . The composition of  claim 129 , wherein the composition further comprises an active pharmaceutical ingredient. 
     
     
         158 . The composition of  claim 157 , wherein the active pharmaceutical ingredient is praziquantel.